Evidence map›Paper›PMID 33632165›Full record

ArticleBMC infectious diseases2021

Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approach.

Innocent Kamali, Dale A Barnhart, Françoise Nyirahabihirwe, Jean de la Paix Gakuru, Mariam Uwase, Esdras Nizeyumuremyi, Stephen Walker, Christian Mazimpaka, Jean de Dieu Gatete, Jean Damascene Makuza and 3 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Innocent KamaliPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda. inocek1@gmail.com.
Dale A BarnhartPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Françoise NyirahabihirwePartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Jean de la Paix GakuruPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Mariam UwasePartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Esdras NizeyumuremyiPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Stephen WalkerGlaxoSmithKline, Philadelphia, PA, USA.
Christian MazimpakaPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Jean de Dieu GatetePartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Jean Damascene MakuzaRwanda Biomedical Centre, IHDPC, Kigali, Rwanda.
Janvier SerumondoRwanda Biomedical Centre, IHDPC, Kigali, Rwanda.
Fredrick KateeraPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.
Jean d'Amour NdahimanaPartners In Health/Inshuti Mu Buzima, Rwinkwavu, Rwanda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo eliminate hepatitis C, Rwanda is conducting national mass screenings and providing to people with chronic hepatitis C free access to Direct Acting Antivirals (DAAs). Until 2020, prescribers trained and authorized to initiate DAA treatment were based at district hospitals, and access to DAAs remains expensive and geographically difficult for rural patients. We implemented a mobile clinic to provide DAA treatment initiation at primary-level health facilities among people with chronic hepatitis C identified through mass screening campaigns in rural Kirehe and Kayonza districts.

methodsThe mobile clinic team was composed of one clinician authorized to manage hepatitis, one lab technician, and one driver. Eligible patients received same-day clinical consultations, counselling, laboratory tests and DAA initiation. Using clinical databases, registers, and program records, we compared the number of patients who initiated DAA treatment before and during the mobile clinic campaign. We assessed linkage to care during the mobile clinical campaign and assessed predictors of linkage to care. We also estimated the cost per patient of providing mobile services and the reduction in out-of-pocket costs associated with accessing DAA treatment through the mobile clinic rather than the standard of care.

resultsPrior to the mobile clinic, only 408 patients in Kirehe and Kayonza had been initiated on DAAs over a 25-month period. Between November 2019 and January 2020, out of 661 eligible patients with hepatitis C, 429 (64.9%) were linked to care through the mobile clinic. Having a telephone number and complete address recorded at screening were strongly associated with linkage to care. The cost per patient of the mobile clinic program was 29.36 USD, excluding government-provided DAAs. Providing patients with same-day laboratory tests and clinical consultation at primary-level health facilities reduced out-of-pocket expenses by 9.88 USD.

conclusionThe mobile clinic was a feasible strategy for providing rapid treatment initiation among people chronically infected by hepatitis C, identified through a mass screening campaign. Compared to the standard of care, mobile clinics reached more patients in a much shorter time. This low-cost strategy also reduced out-of-pocket expenditures among patients. However, long-term, sustainable care would require decentralization to the primary health-centre level.

Indexed as

AgedAntiviral AgentsFemaleHepacivirusHepatitis C, ChronicHumansMaleMass ScreeningMiddle AgedMobile Health UnitsRural HealthRwandaAntiviral AgentsHepatitis CMobile clinicRural healthRwanda

Identifiers

PMID33632165
PMCPMC7908655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.